Neovascular Age-Related Macular Degeneration: Insights Into Achieving Longer Duration of Treatment

This program is intended for AAO 2019 attendees only.


Activity Chair
Sophie J. Bakri, MDProfessor of OphthalmologyMayo ClinicRochester, MN
Faculty
Nancy M. Holekamp, MDDirector, Retina ServicesPepose Vision InstituteProfessor of Clinical OphthalmologyWashington University School of MedicineSt. Louis, MO
Arshad M. Khanani, MD, MAManaging PartnerDirector of Clinical ResearchDirector of FellowshipSierra Eye AssociatesClinical Associate ProfessorUniversity of NevadaReno, NV

Overview
Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of patients with neovascular age-related macular degeneration (nAMD). However, it has also introduced new problems—notably patients’ treatment burden of undergoing frequent intraocular injections. Continuing research on the use of various treatment regimens and on emerging anti-VEGF medications suggests opportunities to optimize nAMD therapy and better balance reductions in treatment frequency with achieving and maintaining improvements in visual acuity. In this educational activity, expert faculty will examine the burden of current anti-VEGF treatment protocols as well as the latest clinical trial data on investigational anti-VEGF agents and their mechanisms of action.






Agenda
5:30 AMRegistration and Breakfast
6:30 AM Introduction and PretestSophie J. Bakri, MD
6:40 AM Neovascular AMD: Defining the Burden Associated With TreatmentNancy M. Holekamp, MD
7:00 AM Embracing New Mechanisms for nAMD TreatmentSophie J. Bakri, MD
7:20 AM State-of-the-Science Review: Clinical TrialsArshad M. Khanani, MD, MA
7:45 AMPosttest and Question and Answer
8:00 AMConclusion


Learning Objectives
Upon successful completion of this activity, participants should be better able to:


Review results from long-term extension trials using pro re nata (PRN), fixed-interval, and treat-and-extend anti-VEGF dosing to have a better understanding how dosing regimen affects visual outcomes in patients with nAMD. 




Assess new agents and delivery techniques that require less frequent administration to achieve effective therapy in patients with nAMD.


Examine the unique mechanisms of action for emerging treatments for nAMD and their ability to lessen the burden of treatment.




Target Audience
The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with nAMD. 


This continuing medical education activity is provided by Vindico Medical Education.
This activity is supported by an educational grant from Allergan, Inc.
This activity is not affiliated with the official program of AAO 2019.
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.
Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee.